155 results about "Tissue fibrosis" patented technology

The present invention provides compositions and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compounds are capable of simultaneously stimulating the epithelium regrowth, inhibiting the fibroblast proliferation, decreasing the collagen deposit, suppressing the fibrogenic growth factor, subsiding the proinflammatory cytokine and modulating the expression of cell cycle genes, tumor suppressors and oncogenes, and are useful to increase the therapeutic gain in radiotherapy and chemotherapy, which results in decrease of skin swelling and inflammation, promotion of epithelium healing in mucosa and dermis, decrease of xerostomia, prevention/reduction of severity of plantar-palmar syndrome, prevention of tissue fibrosis, ulceration, necrosis and tumorigenesis, and increase of tumor growth inhibition and tumor therapy effectiveness.

Use of an inhibitor of a Hedgehog signalling pathway, or an inhibitor of a pathway which is a target of the Hedgehog signalling pathway in the preparation of a medicament for treatment of epithelial cell hyperplasia, fibrosis of tissue, inflammation, cancer or an immune disorder.

The invention relates to a screening method for a medicine for targeting NS5ATP9 (HCV NS5A-transactivated protein 9) prevention or treatment of tissue fibrosis and tissue sclerosis, and the medicine obtained by screening using the method. NS5ATP9 significantly regulates the expression of extracellular matrix collagen and non-collagen glycoprotein and affects the occurrence and development of tissue fibrosis by regulating a TGFbeta1/Smad3 signaling pathway; and the NS5ATP9 promotes the apoptosis of hepatic stellate cells, inhibits the proliferation of the hepatic stellate cells and regulates extracellular matrix deposition by regulating the phosphorylation level and the intracellular translocation condition of a Smad3 protein. TDF/TAF can effectively regulate the expression of NS5ATP9 gene,and is verified in CCl4-induced mouse liver fibrosis model, and the TDF/TAF achieves significant effects in the prevention or treatment of CCl4-induced liver fibrosis in mice.

The invention relates to the technical field of medicine, in particular to the use of 13-methylamino-18-thiomatrine compound (I) and its salts in the preparation of anti-fibrosis drugs. The present invention proves from cytological tests that 13-methylamino-18-thiomatrine can inhibit proliferation and activation of extracellular matrix producing cells hepatic stellate cells, and inhibit fibrotic liver epithelial cell-mesenchymal transition. In addition, it also has inhibitory effects on various other extracellular matrix-producing cells that lead to organ or tissue fibrosis. Animal experiments have proved that 13-methylamino-18-thiomatrine has a very significant anti-hepatic fibrosis effect. The results show that 13-methylamino-18-thiomatrine has definite anti-hepatic fibrosis or fibrosis of other tissues and organs, and can be used to prepare medicines for preventing and treating liver fibrosis or fibrosis of other tissues and organs.

The invention relates to application of anti-aging gene segments and protein products of the anti-aging gene segments in treating chronic renal failure, in particular to application of secretory type Klotho genes and proteins of the Klotho genes in preparing medicine for treating chronic renal failure. According to experiments, the secretory type Klotho has remarkable effect of restraining development of kidney tissue fibrosis and chronic renal failure and has no obvious side and toxic effects, so that the secretory type Klotho can be used for preparing medicines for treating chronic renal failure and particularly used for preparing medicines capable of effectively restraining and delaying development of chronic renal failure.

The invention provides silk fibroin nanoparticles and drug-loading silk fibroin nanoparticles. The silk fibroin nanoparticles are prepared by a method comprising the following steps: dissolving silk fibroin in water, and keeping the water in which the silk fibroin is dissolved at 2-6 DEG C for 2-8h, so that a silk fibroin solution is obtained; mixing the silk fibroin solution with an organic solvent at the volume ratio of 1 to (4-8), and implementing stirring so as to obtain a nanoparticle suspension, wherein the organic solvent is selected from ethanol, isopropanol or acetone; implementing centrifugal separation on the nanoparticle suspension, washing the nanoparticle suspension by virtue of de-ionized water, and implementing centrifuging, so that a nanoparticle precipitate is obtained; and dispersing the nanoparticle precipitate by virtue of de-ionized water, so that the silk fibroin nanoparticles are obtained. The drug-loading silk fibroin nanoparticles can improve intake of drugs in cells and prolong retention time of the drugs; the drug-loading silk fibroin nanoparticles have the advantages of being effective, long-acting and targeted in cells and the drug-loading silk fibroin nanoparticles are conducive to the improvement of bioavailability of the drugs; the silk fibroin nanoparticles are excellent in biological adhesion and free from immunogenicity; and the silk fibroin nanoparticles are free from obvious inflammatory response and tissue fibrosis, and are excellent in biocompatibility and safety.

The invention discloses a quantitative fast frequency-locked magnetic resonance imaging method. Data acquisition of magnetic resonance imaging signals corresponding to different spin lock pulses in acontinuous scanning period is completed, and the data fills the same position in K space, so that T1rhomapping images finally obtained corresponding to the different spin lock pulses have high matching degree and can be used for judging tissue fibrosis indexes and diagnosing a tissue edema state; the effects of arrhythmia, uneven breathing and the like on the quality of the T1rhomapping images areminimized, and physical state and ability to suspend breathing and the like of a tester are not strictly required, so that scanning time required to obtain the T1rhomapping images is greatly shortened and the research and promotion of a T1rhomapping imaging technology in the field of clinical medical detection is further developed; in addition, the spin lock pulses alternate in positive and negative phases in adjacent RF excitation pulses, thereby effectively reducing artifacts due to magnetic field uniformity.

The invention discloses a scar and tissue fibration resistant oligomeric double-stranded nucleotide medicine. The sequence of the nucleotide medicine comprises TGACTCA, TTACCTCA, AGCCAGACA and ATGCAGACA nucleic acid sequences or functional equivalents thereof, and the above four core nucleic acid sequences are contained in the sense strand or the antisense strand of the double-stranded decoy nucleotide.

The invention relates to the field of medicaments, in particular to a novel bifunctional cicatrix and tissue fibrosis resistant oligonucleotide medicament. The nucleic acid contains an AP-1 cis-acting component in high affinity binding with AP-1 and a Smad cis-acting component in high affinity binding with Smad.

The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.

The invention relates to protecting functions and applications of FSTL1 in anti-fibrosis steady-state regulation of tissues such as livers, and particularly relates to uses of FSTL1 protein or an FSTL1 regulating compound in preparation of medicines treating tissue fibrosis diseases. The invention also relates to a conditional FSTL1 gene knockout non-human animal model closely related to the degree of tissue fibrosis pathological changes, a preparing method thereof and uses of the model in tissue-fibrosis-preventing medicine screening. Treatment is performed by combining different tamoxifen dosages and different animal growth stages, the systemic or vascular endothelial cell FSTL1 gene knockout non-human animal model is obtained and the model is used for simulating different tissue fibrosis pathological changes.

The invention discloses a purpose of curcumin or a drug-loading system thereof in preparation of the drug for treating penis erection dysfunction. An experiment proves that the curcumin and a curcuminslow release drug film can up-regulate the expression of GAP-43 and MAP-2 to accelerate growth of the nerve axon and can up-regulate the expression of Oct-6 and Krox-20 to accelerate Schwann cells tosynthesize and secrete myelin sheath-associated protein so as to accelerate formation of the nerve axon myelin sheath. Meanwhile, repair and regeneration after a rat suffers from cavernous body nerveinjury, neural pathway continuity of the cavernous body is recovered, and expression of penis tissue nerve terminal nNOS mRNA and protein is increased. The penis erection function of the rat who suffers from the cavernous body nerve injury can be further improved, meanwhile, a penis tissue fibrosis degree is lowered, and rehabilitation of the penis after the cavernous body nerve injury is effectively accelerated. Therefore, the curcumin and the drug-loading system thereof perform a good application prospect in the preparation of the drug for treating the penis erection dysfunction and repairing the cavernous body nerve injury.